Orforglipron (Foundayo)

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist — the first of its kind to receive FDA approval for weight management. Unlike all other GLP-1 receptor agonists currently on the market (semaglutide, tirzepatide, liraglutide), which are peptide-based molecules requiring injection or highly controlled oral delivery conditions, orforglipron is a small organic molecule that is fully orally bioavailable without food restrictions.¹

This distinction is pharmacologically significant: peptide-based oral GLP-1 agents (like oral semaglutide/Rybelsus) are degraded in the stomach and require a specialized absorption-enhancing carrier (SNAC) that only works under fasting conditions with minimal water. Small molecule GLP-1 agonists like orforglipron are absorbed through conventional oral absorption mechanisms and are not subject to these constraints — enabling true once-daily oral dosing without meal timing requirements.¹

Orforglipron was developed by Eli Lilly and received FDA approval in April 2026 under the brand name Foundayo. It is distinct from oral semaglutide (Wegovy pill, approved December 2025), which is a peptide formulation requiring fasting conditions.

Foundayo (orforglipron) is FDA-approved for:¹

• Chronic weight management in adults with an initial BMI of ≥30 kg/m² (obesity), or ≥27 kg/m² (overweight) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity.

Based on the FDA-approved prescribing information:¹

• Starting dose: 0.8 mg orally once daily
• Escalation: After at least 30 days at each dose level, increase as tolerated
• Available doses: 0.8 mg, 3 mg, 6 mg, 12 mg, 17.2 mg
• Maximum dose: 17.2 mg once daily

Tablets should be swallowed whole — do not break, crush, or chew. Take once daily, with or without food, at any time of day. No food or water restrictions apply.

Oral tablet. No food restrictions. No injection required.

Store at controlled room temperature 20°C to 25°C (68°F to 77°F). Orforglipron is light sensitive — keep in the original bottle and carton, replacing the cap after each use. Protect from light.¹

Boxed warning note: Unlike injectable GLP-1 receptor agonists, orforglipron is not pharmacologically active in rats or mice and did not produce thyroid C-cell tumors in rodent studies. However, the FDA label carries a class-level thyroid C-cell tumor warning, noting the human relevance remains unknown.¹

Key considerations:

• Gastrointestinal effects: Nausea, vomiting, diarrhea, and constipation — the same class effects seen with injectable GLP-1 agents — are the most common adverse effects, predominantly during dose escalation.
• Pancreatitis: Cases of acute pancreatitis have been reported with GLP-1 receptor agonists. Discontinue if suspected.
• Gallbladder disease: Rapid weight loss increases risk of cholelithiasis (gallstones).
• Hypoglycemia: Low risk with orforglipron alone; substantially increased risk when combined with insulin or sulfonylureas.
• CYP3A4 interactions: Orforglipron is a CYP3A4 substrate. Strong CYP3A4 inhibitors increase orforglipron exposure; dose modification may be required per the label.
• Oral contraceptives: As with other GLP-1 agents, discuss timing with prescriber.
• Pregnancy: May cause fetal harm based on animal studies. Discontinue when pregnancy is recognized.
• Not for use with other GLP-1 receptor agonists: Concomitant use is not recommended.